*K. J. Williamsb , G.,Vukmirovitsc , V.,Chmelikd , B.,Pfauslera, 1995.A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults,Journal of Antimicrobial Chemotherapy 36 85 -97
Garnacho-MonteroJ,Garcia-GarmendiaJL,BarreroAlmodovarA, 2003.Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis,Crit Care Med 31 2742 -51
KollefMH,ShermanG, .Inadequate antimicrobialtreatment of infections: a risk factor for hospital mortality among criti-cally ill patients,Chest1999 115 462 -74
KumarA,RobertsD, 2006.Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock,Crit Care Med 34 1589 -96
DrusanoGL, 2004.Antimicrobial pharmacodynamics: critical interactions of 'bug and drug',Nat Rev Microbiol 289 -300
AstraZeneca, 2007.Merrem (meropenem) package insert, -
KutiJL,MaglioD,NightingaleCH,NicolauDP, 2003.Economic Benefit of a Meropenem dosage strategy based on pharmacodynamic concepts,Am J Health-Syst Pharm 60 565 -8
Hurst , M.,and H. M.Lamb, 2000.Meropenem: a review of its use in patients in intensive care,Drugs 59 653 -680
KutiJL,MaglioD,NightingaleCH,NicolauDP, 2003.Economic Benefit of a Meropenem dosage strategy based on pharmacodynamic concepts,Am J Health-Syst Pharm 60 565 -8
Giles , L. J.,A. C.Jennings,A. H.Thomson,R. J.Beale,A.McLuckie, 2000.Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration,Crit. Care Med 28 632637 -
Krueger , W. A., T. H.,Schroeder , M.,Hutchison , E. Hoffmann, H. J.,Dieterich , A.,Heininger , C.,Erley , A.,Wehrle , and K.,Unertl, 1998.Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration,Antimicrob. Agents Chemother 42 2421 -2424
Thalhammer , F.,P.Schenk,H.Burgmann,I. ElMenyawi,U. M.Hollenstein,A. R.Rosenkranz,G.Sunder-Plassmann,S.Breyer,K.Ratheiser, 1998.Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration,Antimicrob. Agents Chemother 42 2417 -2420
Ververs , T. F.,A. van Dijk , S. A.,Vinks , P. J.,Blankestijn , J. F.,Savelkoul , J.,Meulenbelt , and F. T.,Boereboom, 2000.Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration,Crit. Care Med 37 2071 -2078
Roberts , J. A.,S.Webb,D.Paterson,K.,US EPA; Estimation Program Interface M. Ho , and J.,Lipman,Jan, 2012.Available review on clinical benefits of continuous from,as of Jan 25 4 -